|
advertisement
|
news roundup
Germany-based CRO/CDMO NUVISAN will integrate large parts of Bayer’s Berlin-based small molecule research unit. The unit features 400 workplaces and a fully operational team, which includes capabilities and capacities spanning the entire drug discovery value chain.
Open Wearables Initiative (OWEAR) is now actively soliciting open source software and datasets from wearable sensors and other connected health technologies. OWEAR is a collaboration designed to promote the effective use of sensor-generated measures of health in clinical research through the open sharing and benchmarking of algorithms and datasets.
|
|
|
advertisement
Advances in RBM Drive the Clinical Trial of the Future
Access an online resource with useful tools and practical information about advances in RBM. The site provides useful white papers, articles, webcasts, and more.
Access all resources
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
|
Patient Power’s Cancer Clinical Trials Survey results show that the majority of patients surveyed were interested in taking part in clinical trials. However, a little under half stated their medical care team had not discussed clinical trials with them.
Articles
Applied Clinical Trials and SCORR Marketing survey report high levels of job satisfaction, but market demand could offer more in the way of compensation and benefits.
|
|
|
advertisement
Virtual, Decentralized, Site-less Trials… What Does it All Mean?
Thursday, March 12, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
Register now
|
|
|
|
Blog Posts
Gains in approving therapies with limited clinical trials and utilizing accelerated review programs, notably to treat rare diseases and deadly cancers were noted by FDA. CDER also reflected a more efficient and predictable review process, as demonstrated by its success in meeting all user fee goals for timely assessments, reviewing 90% of applications in the first review cycle, and approving nearly 70% of new drugs in advance of other countries. |
It is common, and many would assume logical: if the enrollment performance data from an investigator site is known, particularly if there is a lot of this data, one should be able to predict future enrollment performance by extrapolating from this data. Phesi analysis of over 330,000 trial protocols held in our global database shows this approach is flawed.
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
